[Parathyroid and bone. Medical management of primary hyperparathyroidism].
Although the role of medical management for primary hyperparathyroidism (PHPT) is still controversial, there are subsets of symptomatic patients with PHPT who may benefit from medical rather than surgical treatments. Estrogen remains an excellent option for selected postmenopausal women. Bisphophonates may be useful to provide skeletal protection and to treat osteoporosis associated with PHPT.
Kyoto City Hospital, Department of Endocrinology.
Yasato
Y
Komatsu
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology / Q000628:therapy; D049950:Hyperparathyroidism, Primary / Q000150:complications / Q000628:therapy*; D010024:Osteoporosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D010281:Parathyroid Hormone / Q000378:metabolism / Q000502:physiology; D044169:Receptors, Calcium-Sensing / Q000819:agonists; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004967:Estrogens; D010281:Parathyroid Hormone; D044169:Receptors, Calcium-Sensing; D020845:Selective Estrogen Receptor Modulators